Stock SCOL SCANDION ONCOLOGY A/S
Add to a list
To use this feature you must be a member
Log inSign up

Financials Scandion Oncology A/S

Equities

SCOL

DK0061031895

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-06-28 EDT 		5-day change 1st Jan Change
0.29 SEK -5.23% Intraday chart for Scandion Oncology A/S -26.02% -92.74%
05-22 Transcript : Scandion Oncology A/S, Q1 2024 Earnings Call, May 22, 2024
05-22 Scandion Oncology A/S Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024
Capitalization 1 471.7 289.2 76.11 109 7.752
Enterprise Value (EV) 2 471.7 183.5 -1.497 82.53 -59.45
P/E ratio -17.5 x -5.43 x -1.01 x -2.77 x -
Yield - - - - -
Capitalization / Revenue - - - - -
EV / Revenue - - - - -
EV / EBITDA - -3,341,213 x 18,880 x -1,859,258 x -
EV / FCF - -4,015,890 x 21,428 x -1,636,793 x -
FCF Yield - -0% 0% -0% -
Price to Book - - - - -
Nbr of stocks (in thousands) 32,136 32,136 40,707 40,707 40,707
Reference price 3 19.85 12.38 2.800 3.995 0.2900
Announcement Date 21-04-29 22-02-17 23-02-22 24-02-28 -
1SEK in Million2DKK in Million3SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - - - - -
EBITDA - -15.6 -23.86 -56.1 -82.08 -45.53
EBIT 1 -9.935 -15.6 -23.89 -56.16 -82.22 -45.8
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -9.958 -15.55 -20.65 -57.21 -82.2 -44.7
Net income 1 -8.183 -12.18 -16.27 -51.7 -76.7 -39.2
Net margin - - - - - -
EPS 2 -0.8500 -0.6395 -0.8296 -1.610 -1.884 -0.9631
Free Cash Flow 1 -11.32 -7.741 -162.4 117.1 -44.78 -40.11
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 20-04-30 20-04-30 21-04-29 22-03-24 23-03-28 24-03-15
1DKK in Million2DKK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q1
Net sales -
EBITDA -
EBIT -
Operating Margin -
Earnings before Tax (EBT) -
Net income 1 -12.92
Net margin -
EPS 2 -0.5643
Dividend per Share -
Announcement Date 22-05-19
1DKK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024
Net Debt 1 - - - - -
Net Cash position 1 - 106 77.6 26.5 67.2
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - -45.7 -69.9 -50.4 -
ROE (net income / shareholders' equity) - - -87.7% -77.3% -
ROA (Net income/ Total Assets) - - - - -
Assets - - - - -
Book Value Per Share - - - - -
Cash Flow per Share - - - - -
Capex - 0.32 0.41 - -
Capex / Sales - - - - -
Announcement Date 21-04-29 22-02-17 23-02-22 24-02-28 -
1DKK in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SCANDION ONCOLOGY A/S Stock Scandion Oncology A/S
-92.74% 1.11M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.20% 121B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+19.67% 113B
ARGENX SE Stock argenx SE
+18.95% 26.02B
BIONTECH SE Stock BioNTech SE
-23.86% 19.39B
GENMAB A/S Stock Genmab A/S
-19.03% 15.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.90% 15.09B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.14% 15.06B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+63.85% 14.93B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.49% 13.85B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. SCOL Stock
  4. Financials Scandion Oncology A/S